Gestala Raises 150M CNY for Ultrasound BCI
💡China's $21M-funded ultrasound BCI challenges Neuralink with non-invasive deep-brain tech (AI team aboard)
⚡ 30-Second TL;DR
What Changed
Raised 150M CNY angel round from Guo Sheng Capital, Dao Tong, Qingsong Capital, Gobi VC, and others
Why It Matters
This funding boosts non-invasive BCI development in China, leveraging clinical resources and manufacturing to compete globally. It could accelerate treatments for pain, depression, and neurodegeneration, expanding AI-neurotech applications.
What To Do Next
Evaluate ultrasound neuromodulation APIs from similar neurotech firms for AI-driven BCI prototypes.
🧠 Deep Insight
Web-grounded analysis with 6 cited sources.
🔑 Enhanced Key Takeaways
- •Gestala (Gestalt Chengdu Technology Co., Ltd.) was officially established on an early 2026 date in Chengdu High-Tech Zone’s Tianfu International Bio City, with additional operations in Shanghai's Brain Intelligence World BCI industrial cluster[3].
- •Co-founder Phoenix Peng (also called Peng Lei) previously served as co-founder and CEO of NeuroXess (formerly BrainTiger), a developer of invasive BCI implants, before leaving to pursue ultrasound technology[1][3][5].
- •Early clinical trials of Gestala's ultrasound device showed a single session reduced chronic pain scores by 50%, with effects lasting one to two weeks; first-generation clinic-based product rollout expected by Q3 2026[5].
- •Gestala plans to develop a second-generation wearable home helmet after the initial stationary clinic system, expanding applications to depression, stroke recovery, Alzheimer's, and sleep disorders[1][4].
📊 Competitor Analysis▸ Show
| Feature | Gestala | Neuralink | Merge Labs |
|---|---|---|---|
| Invasiveness | Non-invasive (ultrasound) | Invasive (implants/threads) | Non-invasive (ultrasound) |
| Brain Access Depth | Whole-brain potential | Limited areas (e.g., motor cortex) | Whole-brain potential |
| Primary Targets | Chronic pain, depression, stroke | Motor control, paralysis | Chronic pain, depression |
| Clinical Status | Early trials (50% pain reduction, 1-2 weeks effect)[5] | Human implants/trials | Early stage (OpenAI-backed)[1] |
| Challenges | Skull interference, signal reading[1][2] | Surgery risks | Technical hurdles unsolved[1] |
🛠️ Technical Deep Dive
- •Uses focused ultrasound (high-frequency sound waves) to modulate neural activity by targeting regions like the anterior cingulate cortex for chronic pain relief, with effects lasting up to one week in pilot studies[4].
- •Aims for whole-brain signal reading via detecting blood flow changes (functional ultrasound imaging), contrasting with electrode-based systems limited to specific areas[1][2][5].
- •First-generation device is a stationary clinic system; future wearable helmet for home use planned[1][4].
- •Leverages established focused ultrasound approvals for Parkinson's and tumors as clinical foundation, but brain signal interpretation remains a major engineering challenge[2][4].
🔮 Future ImplicationsAI analysis grounded in cited sources
⏳ Timeline
📎 Sources (6)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
Weekly AI Recap
Read this week's curated digest of top AI events →
👉Related Updates
AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗